Objective: We aimed to compare cisplatin and oxaliplatin-based therapies in patients with HER2-positive gastric cancer.

Material and Method: We evaluated clinicopathological and treatment data of the patients who used cisplatin, fluoropyrimidine, trastuzumab (CFT) or oxaliplatin, capecitabine, trastuzumab (OCT) retrospectively. The clinicopathological characteristics of the two groups were assessed, as well as their survival results.

Results: Twenty-three (57.5%) patients received CFT regimen, and seventeen (42.5%) patients OCT regimen. Clinicopathological features and ECOG performance status were similar in between groups. Median progression-free survival was 12 (CI 95%, 10.8-13.1) months in the CFT group and 8.6 (CI 95%, 5.9-11.3) months in the OCT group (p =0.39). Median overall survival (OS) was 21.7 (95% CI 16.9-26.4) months in the CFT group and 13.6 (CI 95%, 6.7-20.5) months in the OFT group. In univariate analysis, the change in OS between the two groups was statistically significant; however, the findings were not confirmed in multivariate analysis.

Conclusion: There was a trend in the study that patients treated with CFT had better OS compared to OCT. This situation did not reach statistical significance. Treatment-related toxicities were similar between the two groups.